Bio-Rad Laboratories, Inc.
corporate_fare Company Profile
Bio-Rad Laboratories, Inc. (NYSE:BIO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 13 items for BIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for BIO spans 10-Q, 8-K, DEF 14A, 10-K.
Recent high-impact activity:
- Bio-Rad Q3 Revenue Edges Past Estimates as Clinical Diagnostics Offsets Life Science Weakness
- Bio-Rad 10-Q Details Q3: $458.6M GAAP Profit Is a Sartorius Mark; Operations Lost $49.7M
- Bio-Rad Q3 2026: Non-GAAP EPS $2.65, GAAP Profit $458.6M on Sartorius Mark, Outlook Held
- Bio-Rad to Slash Jobs, Shut Facilities in $80–90M Restructuring Push
- Bio-Rad Q2 Revenue Beats by $27M on Diagnostics Strength, Reaffirms Outlook
Financial Snapshot
Short Interest & Short Volume
5.07 days to coverFINRA reported short interest of 1,156,915 shares in BIO as of the October 30, 2026 settlement, a 5.4% increase from the prior period — about 5.1 days to cover at its recent average daily volume. On November 20, 2026, 84.7% of BIO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.